2322-45-4

Basic information

• Product Name: 2-bromo-2-methyl-N-phenylpropanamide
• Synonyms: 2-Bromo-2-methyl-N-phenylpropanamide; propanamide, 2-bromo-2-methyl-N-phenyl-
• CAS NO: 2322-45-4
• Molecular Formula: C₁₀H₁₂BrNO
• Molecular Weight: 242.1124
• Mol File: 2322-45-4.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 356.2°C at 760 mmHg
• Flash Point: 169.3°C
• Density: 1.434g/cm³
• Vapor Pressure: 2.96E-05mmHg at 25°C
• Refractive Index: 1.596
• CAS DataBase Reference: 2-bromo-2-methyl-N-phenylpropanamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-2-methyl-N-phenylpropanamide(2322-45-4)
• EPA Substance Registry System: 2-bromo-2-methyl-N-phenylpropanamide(2322-45-4)

Safety Data

• Hazardous Substances Data: 2322-45-4(Hazardous Substances Data)

Upstream product

• 20469-89-0 2-bromo-2-methylpropionyl chloride 
• 62-53-3 aniline 
• 21718-11-6 N-phenyl-S-(4-trifluoromethylphenyl) sulfonamide 
• 4406-41-1 N-phenylisobutyramide 
• 20769-85-1 2-bromoisobutyric acid bromide 

Downstream Products

• 4406-41-1 N-phenylisobutyramide 
• 116275-14-0 3-anilino-2,2-dimethyl-3-oxo-propanoic acid phenylmethyl ester 
• 67691-43-4 3-anilino-2,2-dimethyl-3-oxo-propanoic acid methyl ester 
• 74262-30-9 2-methyl-N-phenyl-2-(phenylamino)propanamide 
• 2760-38-5 2-hydroxy-2-methylpropionanilide 
• 128966-04-1 α-phenoxy-isobutyric acid anilide 
• 47002-22-2 2,2-dimethyl-N-phenyl-3-piperidin-1-yl-propionamide 
• 1611-83-2 2-methyl-N-phenylacrylamide 

Relevant articles and documents

Optimization of bifunctional piperidinamide derivatives as σ1R Antagonists/MOR agonists for treating neuropathic pain

Here, we describe the optimization, synthesis, and associated pharmacological analgesic activities of a new series of bifunctional piperidinamide derivatives as sigma-1 receptor (σ1R) antagonists and mu opioid receptor (MOR) agonists. The new compounds were evaluated in vitro in σ1R and MOR binding assays. The most promising compound 114 (also called HKC-126), showed superior affinities for σ1R and MOR and good selectivity to additional receptors related to pain. Compound 114 showed powerful dose-dependent analgesic effects in the acetic acid writhing test, formalin test, hot plate test, and chronic constriction injury (CCI) neuropathic pain model. In contrast to an equianalgesic dose of fentanyl, compound 114 produced fewer opioid-like side effects, such as reward liability, respiratory depression, physical dependence, and sedation. Lastly, the pharmacokinetic properties of this drug were also acceptable, and these results suggest that compound 114, as a mixed σ1R/MOR ligand, has potential for treating neuropathic pain.

SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN

The present invention relates to substituted amide derivatives of formula (I) having dual pharmacological activity towards both the sigma (σ) receptor, and the p-opioid receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

Copper-Salt-Promoted Carbocyclization Reactions of α-Bromo- N -arylacylamides

A mild and convenient synthetic method for oxindoles and α-arylacylamides bearing an all carbon quaternary stereocenter from the readily available α-bromo-N-arylacylamides has been developed. This Cu(acac)2/Phen-promoted radical cyclization rea